Takeda Pharma USA Inc v. Sun Pharmaceutical Industries Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Takeda Pharmaceuticals U.S.A., Inc. (Delaware)
  • Defendant: Sun Pharmaceutical Industries Ltd. (India)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-08064, D.N.J., 07/01/2026
• Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey because Defendant Sun Pharmaceutical Industries Ltd. develops, markets, and sells generic pharmaceutical products throughout the United States, including in the district, and will direct its activities related to the accused product toward New Jersey. The complaint also notes that Sun has previously availed itself of the New Jersey courts.
• Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of the cancer drug ICLUSIG® (ponatinib) infringes four U.S. patents covering specific crystalline forms of ponatinib hydrochloride and methods of its use.
• Technical Context: The technology relates to pharmaceutical polymorphism, which involves identifying and characterizing specific stable crystalline structures of an active pharmaceutical ingredient (API) to ensure drug product consistency, stability, and bioavailability.
• Key Procedural History: The complaint certifies that the matter in controversy involves patents and a plaintiff that have been the subject of prior, now-dismissed litigation in the same district against other generic manufacturers (Teva Pharmaceuticals and Apotex Inc.), suggesting an established pattern of patent enforcement by Takeda for its ICLUSIG® franchise.

Case Timeline

Date	Event
2012-12-12	Priority Date for '470, '895, and '897 Patents
2016-11-15	U.S. Patent No. 9,493,470 Issued
2021-12-07	U.S. Patent No. 11,192,895 Issued
2021-12-07	U.S. Patent No. 11,192,897 Issued
2022-07-12	U.S. Patent No. 11,384,086 Issued
2026-05-21	Sun provides Paragraph IV notice to Takeda
2026-07-01	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,493,470

• Patent Identification: U.S. Patent No. 9,493,470, "Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt," issued November 15, 2016 Compl. ¶4

The Invention Explained

• Problem Addressed: The development of a pharmaceutical drug requires a consistent and stable form of the active pharmaceutical ingredient (API). The patent background explains that polymorphism-the ability of a compound to exist in multiple crystalline forms-can lead to inconsistencies in manufacturing and variable drug performance if not properly controlled '470 Patent, col. 3:9-24
• The Patented Solution: The invention describes and claims specific, distinct crystalline forms (polymorphs and pseudopolymorphs) of ponatinib and its monohydrochloride salt '470 Patent, abstract These forms are defined by unique physical characteristics, such as their X-ray powder diffraction (XRPD) patterns and thermal properties, which allow for their reproducible preparation and formulation into a drug product '470 Patent, col. 3:55-67 '470 Patent, FIG. 1
• Technical Importance: Identifying and patenting specific, stable crystalline forms of an API is critical for ensuring the safety, efficacy, and quality of a drug product, as it provides a basis for consistent manufacturing and predictable bioavailability.

Key Claims at a Glance

• The complaint alleges infringement of "one or more claims" without specifying which ones Compl. ¶32
• A representative independent claim is Claim 7, which claims a specific crystalline form of ponatinib hydrochloride designated as Form A. Its elements are:
  • A crystalline form of ponatinib hydrochloride,
  • characterized by an x-ray powder diffraction pattern comprising 2θ values (±0.3) at 5.9, 7.1, 12.5, 19.3, 23.8, and 26.1.
• The complaint reserves the right to assert other claims, which may include dependent claims that further refine the characteristics of the crystalline forms or claims directed to methods of treatment Compl. ¶32

U.S. Patent No. 11,192,895

• Patent Identification: U.S. Patent No. 11,192,895, "Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt," issued December 7, 2021 Compl. ¶5

The Invention Explained

• Problem Addressed: As a continuation of the work in the '470 Patent, the '895 patent addresses the same fundamental problem in pharmaceutical development: the need to identify and control the solid-state form of an API to ensure manufacturing consistency and predictable performance of the final drug product '895 Patent, col. 3:9-24
• The Patented Solution: The patent discloses and claims specific crystalline forms of ponatinib hydrochloride, defining them by their unique analytical signatures, particularly their XRPD patterns '895 Patent, abstract For example, the patent describes and provides characterization data for numerous distinct forms, including anhydrates, hydrates, and solvates, such as Form A '895 Patent, col. 14:40-50 '895 Patent, FIG. 3
• Technical Importance: This invention provides further intellectual property protection over specific, commercially viable solid forms of the ponatinib API, which is essential for maintaining market exclusivity and ensuring patient safety through consistent product quality.

Key Claims at a Glance

• The complaint generally alleges infringement of "one or more claims" Compl. ¶41
• A representative independent claim is Claim 1, which claims crystalline Form A of ponatinib hydrochloride, but with a different set of defining peaks than in the '470 patent. Its elements are:
  • A crystalline Form A of ponatinib hydrochloride,
  • characterized by an X-ray powder diffraction (XRPD) pattern comprising 2θ values at 12.5, 19.3, 23.8, and 26.1.
• The complaint reserves the right to assert other claims Compl. ¶41

Multi-Patent Capsule

• Patent Identification: U.S. Patent No. 11,192,897, "Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt," issued December 7, 2021 Compl. ¶6

• Technology Synopsis: This patent, belonging to the same family as the previously discussed patents, addresses the technical challenge of polymorphism by identifying and characterizing specific solid-state forms of the ponatinib hydrochloride API '897 Patent, col. 3:9-24 The invention provides defined crystalline structures, such as Form A, that can be reliably manufactured into a stable and consistent pharmaceutical product '897 Patent, abstract '897 Patent, col. 14:40-49

• Asserted Claims: The complaint asserts "one or more claims" Compl. ¶50 Independent claim 1 recites a crystalline Form A of ponatinib hydrochloride characterized by an XRPD pattern with peaks at 12.5, 19.3, and 26.1 (2θ).

• Accused Features: Sun's proposed generic ponatinib hydrochloride tablets are alleged to embody the claimed crystalline form of ponatinib hydrochloride (Compl. ¶¶26; Compl. ¶50).

• Patent Identification: U.S. Patent No. 11,384,086, "Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt," issued July 12, 2022 Compl. ¶7

• Technology Synopsis: The complaint does not provide the '086 patent, precluding a detailed synopsis of its technology.

• Asserted Claims: The complaint asserts "one or more claims" Compl. ¶59 The specific claims are not identified.

• Accused Features: Sun's proposed generic ponatinib hydrochloride tablets are alleged to embody the invention of one or more claims of the '086 patent (Compl. ¶¶26; Compl. ¶59).

III. The Accused Instrumentality

• Product Identification: The accused instrumentality is Sun's ANDA Product: ponatinib hydrochloride tablets in 10 mg, 15 mg, 30 mg, and 45 mg strengths, for which Sun submitted ANDA No. 218126 to the FDA (Compl. ¶¶1; Compl. ¶26).
• Functionality and Market Context:
  • The accused product is intended to be a generic version of Takeda's branded drug, ICLUSIG® (Compl. ¶¶1; Compl. ¶30).
  • ICLUSIG® (ponatinib) is a prescription medicine indicated for the treatment of adult patients with certain types of acute lymphoblastic leukemia and chronic myeloid leukemia Compl. ¶8
  • The complaint alleges that Sun is the "fourth largest specialty generic pharmaceutical company in the world" and that it intends to manufacture, use, sell, and/or import its ANDA Product in the United States upon FDA approval, prior to the expiration of the patents-in-suit Compl. ¶15 Compl. ¶27

IV. Analysis of Infringement Allegations

The complaint does not provide specific factual allegations mapping elements of the accused product to the patent claims, which is typical for a Hatch-Waxman complaint filed upon notice of an ANDA submission. The central theory of infringement is that by seeking FDA approval for a generic version of ICLUSIG®, Sun necessarily represents that its product contains the same active ingredient, and that this active ingredient is a crystalline form of ponatinib hydrochloride covered by one or more claims of the patents-in-suit (Compl. ¶¶1; Compl. ¶30; Compl. ¶32; Compl. ¶41). Consequently, a claim chart cannot be constructed based on the complaint's allegations.

No probative visual evidence provided in complaint.

• Identified Points of Contention:
  • Characterization Questions: The central dispute will likely be a battle of experts over analytical chemistry data. A primary question for the court will be whether the specific solid form of ponatinib hydrochloride in Sun's ANDA product, as characterized by techniques like XRPD, falls within the scope of the crystalline forms claimed in Takeda's patents.
  • Scope Questions: The infringement analysis may turn on the interpretation of the phrase "characterized by an x-ray powder diffraction pattern comprising" the recited 2θ values. A point of contention may be whether this language requires an exact match, or if it tolerates minor variations in peak positions or intensities, or the presence of additional peaks not listed in the claims.

V. Key Claim Terms for Construction

• The Term: "crystalline form"

• Context and Importance: This term is fundamental, as the patents claim specific polymorphic forms of ponatinib hydrochloride, distinguishing them from amorphous material or other polymorphs. The entire dispute hinges on whether Sun's product is the claimed "crystalline form." Practitioners may focus on this term because the patents explicitly define multiple distinct forms (e.g., Form A, Form B, etc.), suggesting the term is intended to be highly specific and limited to the particular form recited in a given claim '895 Patent, FIG. 1

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification's general discussion of polymorphism could be used to argue for a meaning that encompasses any material with a repeating, ordered solid-state structure, as opposed to a disordered amorphous solid '895 Patent, col. 3:9-14
  • Evidence for a Narrower Interpretation: The patents provide exacting definitions for each named form using precise analytical data (e.g., specific XRPD peaks, DSC endotherms), and the claims themselves recite these defining characteristics '895 Patent, cl. 1 '470 Patent, cl. 7 This suggests that "crystalline form" in a claim is strictly limited to the specific polymorph defined by that claim's parameters.

• The Term: "characterized by an x-ray powder diffraction pattern comprising 2θ values"

• Context and Importance: This phrase defines the claimed crystalline forms by their most important analytical fingerprint. The interpretation of "comprising" will be critical. Practitioners may focus on this term because its open-ended nature ("comprising") could be the basis for arguments about whether the presence of additional, unlisted peaks in the accused product's XRPD pattern takes it outside the claim scope.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The word "comprising" is well-established in patent law to mean the list that follows is not exhaustive. This supports an interpretation that an accused product can infringe even if its XRPD pattern contains additional peaks not recited in the claim, as long as it has the required ones.
  • Evidence for a Narrower Interpretation: The specification provides detailed XRPD figures (e.g., '895 Patent, FIG. 3; '470 Patent, FIG. 3) that show a complete pattern with specific relative intensities. A defendant might argue that to be "characterized by" the pattern, an accused product must exhibit a substantially identical overall pattern, not just the presence of a subset of peaks, and that the recited peaks must be of a certain prominence.

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement. The inducement allegation is based on the assertion that Sun's product label will instruct or encourage physicians and patients to administer the drug for its approved indications, which allegedly directly infringes Takeda's method-of-use claims Compl. ¶11 Compl. ¶35 The contributory infringement allegation is based on the assertion that Sun's product is especially adapted for an infringing use and has no substantial non-infringing use Compl. ¶36
• Willful Infringement: The complaint does not use the term "willful" but alleges that Sun has had "knowledge" of the patents-in-suit since at least the date of its ANDA submission Compl. ¶37 Compl. ¶46 Compl. ¶55 Compl. ¶64 It further requests a finding that the case is "exceptional" and an award of attorneys' fees under 35 U.S.C. § 285, which lays the groundwork for a potential argument for enhanced damages based on post-suit infringement Compl. ¶39 Compl. ¶48 Compl. ¶57 Compl. ¶66

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of analytical fact-finding: does Sun's proposed generic product contain a crystalline form of ponatinib hydrochloride that, when analyzed, exhibits the specific X-ray powder diffraction peaks recited in the asserted claims? The case will likely devolve into a battle of competing expert testimony over the interpretation of analytical data.
• A key question of claim construction will be the scope of the term "characterized by." The court will need to determine if infringement requires only the presence of the recited XRPD peaks, or if it demands a more holistic similarity to the reference patterns disclosed in the patents, considering relative peak intensities and the absence of significant, non-recited peaks.
• Regarding the method claims, a central question will be one of induced infringement: assuming the underlying method claims are valid, does Sun's proposed product label, by virtue of being a copy of the ICLUSIG® label, contain sufficient instruction and encouragement for physicians to prescribe the drug in a manner that directly infringes Takeda's patented methods of treatment?